Manning & Napier Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 102,792 shares of the biopharmaceutical company’s stock, valued at approximately $12,987,000.
Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $215,000. Sivia Capital Partners LLC boosted its stake in shares of Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC grew its holdings in shares of Gilead Sciences by 12.0% in the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after purchasing an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC increased its stake in Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Gilead Sciences
In related news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This represents a 19.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This represents a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 87,000 shares of company stock worth $11,562,960. Insiders own 0.30% of the company’s stock.
Analyst Upgrades and Downgrades
Gilead Sciences Trading Up 0.4%
NASDAQ:GILD opened at $146.74 on Tuesday. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The stock has a market cap of $181.95 billion, a P/E ratio of -54.96 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock has a 50-day simple moving average of $132.42 and a 200-day simple moving average of $136.57.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.01 earnings per share. As a group, analysts anticipate that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s payout ratio is -122.85%.
About Gilead Sciences
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
